NDC 10122-141

Retavase

Reteplase

Retavase is a Kit in the Human Prescription Drug category. It is labeled and distributed by Chiesi Usa, Inc.. The primary component is .

Product ID10122-141_401c47cc-bb82-40e1-a77a-9783c5fc92f2
NDC10122-141
Product TypeHuman Prescription Drug
Proprietary NameRetavase
Generic NameReteplase
Dosage FormKit
Marketing Start Date1996-10-30
Marketing CategoryBLA / BLA
Application NumberBLA103786
Labeler NameChiesi USA, Inc.
Active Ingredient Strength0
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 10122-141-02

1 KIT in 1 BOX (10122-141-02) * 10 mL in 1 VIAL, SINGLE-USE * 10 mL in 1 SYRINGE (10122-142-01)
Marketing Start Date1996-10-30
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 10122-141-02 [10122014102]

Retavase KIT
Marketing CategoryBLA
Application NumberBLA103786
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date1996-10-30

Drug Details

OpenFDA Data

SPL SET ID:e7b63b16-d911-478b-a445-b690a1360b48
Manufacturer
RxNorm Concept Unique ID - RxCUI
  • 763141
  • 763138
  • NDC Crossover Matching brand name "Retavase" or generic name "Reteplase"

    NDCBrand NameGeneric Name
    10122-141Retavasereteplase
    10122-143Retavasereteplase

    Trademark Results [Retavase]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    RETAVASE
    RETAVASE
    88341695 not registered Live/Pending
    EKR THERAPEUTICS, INC.
    2019-03-15
    RETAVASE
    RETAVASE
    75324869 2175074 Dead/Cancelled
    EKR THERAPEUTICS, INC.
    1997-07-15
    RETAVASE
    RETAVASE
    74647641 not registered Dead/Abandoned
    BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION
    1995-03-16

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.